Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 06, 2020	Dec. 31, 2020	Dec. 31, 2021
Successor
Cash Flows from Continuing Operations
Net loss from continuing operations		$ (25,428)	$ (130,854)
Adjustments to reconcile net loss from continuing operations to net cash used in continuing operating activities:
Impairment of goodwill and other intangible assets			28,995
Depreciation		112	1,275
Amortization of intangible assets		229	2,752
Amortization of Convertible Debenture discount		4,717	9,253
Interest on convertible debt paid-in-kind		3,695	8,257
Share-based compensation		2,489	8,629
Change in fair value of warrant liabilities		3,625	19,608
Amortization and write-off of deferred financing costs			1,143
Noncash financing fees			5,948
Loss on disposal of property and equipment			2
Changes in operating assets and liabilities:
Accounts receivable		(262)	(5,327)
Prepaid expenses and other current assets		(491)	(1,530)
Accounts payable and accrued expenses		(3,304)	6,761
Deferred revenue		77	(189)
Other		(13)	(2,075)
Net cash used in continuing operating activities		(14,554)	(47,352)
Cash Flows from Continuing Investing Activities:
Cash from the acquisition of Computex (See Note 4)		269
Purchase of property and equipment		(52)	(2,990)
Proceeds from sale of property and equipment			1
Deferred development costs			(931)
Net cash (used in) provided by continuing investing activities		217	(3,920)
Cash Flows from Continuing Financing Activities:
Net change in line of credit			(7,355)
Payment of taxes from withheld shares			(1,148)
Debt repayments (including capital lease obligations and Promissory Note)		(21)	(6,525)
Proceeds from issuance of promissory note - related party			5,000
Proceeds from issuance of debt			27,000
Proceeds from issuance of Convertible Debentures (See Note 10)		23,103	24,000
Proceeds from issuance of securities		1,500	27,784
Proceeds from exercise of warrants			5,002
Redemption of shares held in trust		(1,004)
Payment of deferred financing fees			(1,872)
Net cash provided by continuing financing activities		23,578	71,886
Cash Flows from Discontinued Operations
Net cash used in operating activities		(889)	5,148
Net cash used in investing activities		(857)	(1,012)
Net cash provided by financing activities		1,137
Net cash provided by (used in) discontinued operations		(609)	4,136
Net change in cash and restricted cash		8,632	24,750
Cash and restricted cash, beginning of period		1,873	10,505
Cash and restricted cash, end of period	$ 1,873	10,505	35,255
Supplemental Disclosures about Cash Flow Information
Cash paid for interest		677	1,058
Cash paid (refunds received) for income taxes		10	266
Supplemental Schedule of Noncash Investing and Financing Activities
Noncash conversion of Debentures to common stock			109,695
Fair value of Penny Warrants related to the issuance of ConvertibleDebentures		27,732	9,223
Noncash acquisition of Computex in exchange for common stock,Convertible Debentures and assumed debt		61,768
Noncash acquisition of Computex in exchange for Convertible Debentures		43,778
Promissory note - related party, exchanged for Convertible Debentures		8,566
Deferred underwriting fees settled via the issuance of common stock and the issuance of subordinated promissory note		3,000
Capital expenditures included in accounts payable and accrued expenses		42	64
Noncash conversion of Series A Preferred to common stock			$ 12,456
Predecessor
Cash Flows from Continuing Operations
Net loss from continuing operations
Adjustments to reconcile net loss from continuing operations to net cash used in continuing operating activities:
Impairment of goodwill and other intangible assets
Depreciation
Amortization of intangible assets
Amortization of Convertible Debenture discount
Interest on convertible debt paid-in-kind
Share-based compensation
Change in fair value of warrant liabilities
Amortization and write-off of deferred financing costs
Noncash financing fees
Loss on disposal of property and equipment
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Deferred revenue
Other
Net cash used in continuing operating activities
Cash Flows from Continuing Investing Activities:
Cash from the acquisition of Computex (See Note 4)
Purchase of property and equipment
Proceeds from sale of property and equipment
Deferred development costs
Net cash (used in) provided by continuing investing activities
Cash Flows from Continuing Financing Activities:
Net change in line of credit
Payment of taxes from withheld shares
Debt repayments (including capital lease obligations and Promissory Note)
Proceeds from issuance of promissory note - related party
Proceeds from issuance of debt
Proceeds from issuance of Convertible Debentures (See Note 10)
Proceeds from issuance of securities
Redemption of shares held in trust
Payment of deferred financing fees
Net cash provided by continuing financing activities
Cash Flows from Discontinued Operations
Net cash used in operating activities	(1,581)
Net cash used in investing activities	(157)
Net cash provided by financing activities	1,989
Net cash provided by (used in) discontinued operations	251
Net change in cash and restricted cash	251
Cash and restricted cash, beginning of period	18	$ 269
Cash and restricted cash, end of period	269
Supplemental Disclosures about Cash Flow Information
Cash paid for interest	384
Cash paid (refunds received) for income taxes	(4)
Supplemental Schedule of Noncash Investing and Financing Activities
Noncash conversion of Debentures to common stock
Fair value of Penny Warrants related to the issuance of ConvertibleDebentures
Noncash acquisition of Computex in exchange for common stock,Convertible Debentures and assumed debt
Noncash acquisition of Computex in exchange for Convertible Debentures
Promissory note - related party, exchanged for Convertible Debentures
Deferred underwriting fees settled via the issuance of common stock and the issuance of subordinated promissory note
Capital expenditures included in accounts payable and accrued expenses	125
Noncash conversion of Series A Preferred to common stock